评估肌层浸润性膀胱癌新辅助化疗后的癌症进展与疾病稳定
本研究回顾性提出并验证将临床分期为cT2N0M0的肌层浸润性膀胱癌新辅助化疗病理无反应者分为疾病稳定(pT2N0M0)和进展(>pT2或pN+),发现两组生存结局不同,且肿瘤大小可预测新辅助化疗无反应者的生存。
要点
- 新辅助化疗无反应者应进一步分为疾病稳定与进展两类。
- 新辅助化疗后疾病稳定者生存与新辅助化疗后进展者不同。
- 肿瘤大小是新辅助化疗无反应者的重要预后生物标志物。
核心结论
- 不同的生存结局提示新辅助化疗无反应者应进一步分为疾病稳定和进展两类。
- 非新辅助化疗疾病稳定患者与新辅助化疗疾病稳定患者生存相当,提示新辅助化疗后疾病稳定可能代表一种化疗耐药但更惰性的疾病表型。
- 肿瘤大小是新辅助化疗无反应者的重要预后生物标志物。
- 未识别出新辅助化疗后疾病进展的临床预测因素,强调需要探索疾病进展的分子和基因组亚型决定因素。
研究设计与样本
- 回顾性识别本机构2005-2014年及美国国家癌症数据库2004-2012年接受根治性膀胱切除术的cT2N0M0期患者进行外部验证。
- 患者被分为疾病稳定(pT2N0M0)或进展(>pT2或pN+)。
- 主要终点为癌症特异性生存(CSS)、总生存(OS)和无复发生存(RFS)。
主要发现
- 在本机构队列中,新辅助化疗后疾病稳定患者(n=17)的OS(P=.05)和RFS(P=.04)优于新辅助化疗后进展患者(n=50),且OS(P=.7)和CSS(P=.09)与非新辅助化疗疾病稳定患者(n=27)相当。
- 多变量Cox比例风险模型显示,肿瘤较大预测更差的OS(风险比[HR]=1.20每厘米,95%置信区间[CI:1.07,1.35])、CSS(HR=1.27,95%CI[1.11,1.45])和RFS(HR=1.24,95%CI[1.09,1.42])。
- 在美国国家癌症数据库中,新辅助化疗后疾病稳定患者(n=223)的OS优于新辅助化疗后进展患者(n=232)(P<.0001),且OS与非新辅助化疗疾病稳定患者(n=950)相当(P=.4)。
- 多变量Cox比例风险模型显示,肿瘤较大(HR=1.03每厘米,95%CI[1.02,1.03])和进展(HR=2.69,95%CI[2.40,3.01])预测更差的OS。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To propose and validate a new approach to stratify clinically staged, organ-confined, muscle-invasive bladder cancer patients (cT2N0M0) who are pathologic non-responders to neoadjuvant chemotherapy (NAC) to better characterize NAC non-response. METHODS: We retrospectively identified radical cystectomy patients with cT2N0M0 disease at our institution (2005-2014) and in the National Cancer Database (2004-2012) for external validation. Patients were stratified as stable (pT2N0M0) or progressors (>pT2 or pN+). The primary end points were cancer-specific survival (CSS), overall survival (OS), and recurrence-free survival (RFS). RESULTS: In the institutional cohort, NAC stable patients (n = 17) had better OS (P = .05) and RFS (P = .04) than NAC progressors (n = 50), and had comparable OS (P = .7) and CSS (P = .09) with non-NAC stable patients (n = 27). Multivariable Cox proportional hazard models showed that larger tumor size predicted worse OS (hazard ratio [HR] = 1.20 per centimeter, 95% confidence interval [CI: 1.07, 1.35]), CSS (HR = 1.27, 95% CI [1.11, 1.45]), and RFS (HR = 1.24, 95% CI [1.09, 1.42]). Similarly, in the National Cancer Database, NAC stable patients (n = 223) had improved OS (P < .0001) compared with NAC progressors (n = 232) and comparable (P = .4) OS with non-NAC stable patients (n = 950). Multivariable Cox proportional hazard model showed that larger tumor size (HR = 1.03 per centimeter, 95% CI [1.02, 1.03]) and progression (HR = 2.69, 95% CI [2.40, 3.01]) predicted worse OS. CONCLUSION: Distinct survival outcomes suggest that NAC non-responders should be further stratified into stable disease and progressors. Comparable survival between non-NAC and NAC stable disease patients suggests that NAC stable disease may represent a chemoresistant but more indolent phenotype on the disease spectrum. Moreover, tumor size is an important prognostic biomarker in NAC non-responders. Clinical predictors of disease progression on NAC were not identified, highlighting the need to explore molecular and genomic subtyping determinants of disease progression.
引用
- Chappidi MR, Kates M, Brant A, et al. Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. Urology. 2017. PMID: 28104421. doi:10.1016/j.urology.2016.10.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。